Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215512 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
A Phase 1 study of Brain Metastases, sponsored by EpicentRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT02215512 is a Phase 1 study of Brain Metastases that has completed, run by EpicentRx. The registered enrollment target is 29 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02215512, a Phase 1 study of Brain Metastases, has completed, sponsored by EpicentRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be assessed. Once a maximum tolerated dose is identified, further (up to approximately 30) participants will be recruited. The study will use MRI to monitor changes in tumor blood flow associated with RRx-001.
Conditions Studied
Interventions
- DRUG RRx-001 + WBRT
Study Locations (5)
Michigan
- University of Michigan - Ann Arbor
- Allegiance Health - Jackson
California
- Providence Saint John's Health Center - Santa Monica
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- The Cancer Institute of New Jersey (Rutgers University) - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-02-06 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215512
The ClinicalTrials.gov registry entry for NCT02215512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (86% lower). The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which RRx-001 + WBRT is the first listed.
NCT02215512 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Michigan, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT02215512 about?
NCT02215512 is a clinical study titled "Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases". In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be assessed. Once a maximum tolerated dose is identified, further (up to appro...
What is the current status of trial NCT02215512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-02-06. Estimated completion is 2020-11-12.
What conditions does trial NCT02215512 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02215512?
The interventions under investigation include: RRx-001 + WBRT (DRUG).
Who is sponsoring clinical trial NCT02215512?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02215512 being conducted?
This trial has 5 study locations across California, Michigan, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
Phase I Study of Fractionated Stereotactic Radiation Therapy
RECRUITING · Phase 1
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.